food and drug administration

Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana.

Our weekly review starts in Georgia, where the governor is expected to sign a medical marijuana reform bill into law.  The law will allow grow houses and production facilities in the state, which will be heavily

Cannabidiol (CBD) competed with Vitamin C as a top ingredient in new cosmetic products this past year, with promises of having anti-inflammatory effects and other healing properties. Amid the hype, at the end of 2018, the Agriculture Improvement Act of 2018, P.L. 115-334 (the “2018 Farm Bill”) was signed into law, changing the marketing of hemp and derivatives of cannabis and further removing hemp from the Controlled Substances Act thereby making it no longer an illegal substance under federal law. See Section 297A. The 2018 Farm Bill amended the definition of “hemp” to specifically include “all derivatives, extracts, cannabinoids,” which has been construed as an attempt to include hemp-based CBD under the definition of industrial hemp. The 2018 Farm Bill allows, subject to certain restrictions, hemp cultivation, along with the sale, transport (including via interstate commerce), and possession of hemp-derived products.
Continue Reading

Welcome to our end of the year wrap-up post for The Week in Weed; it’s hard to believe another year has come and (almost) gone, but the calendar doesn’t lie.  In what we are calling an homage to Dave Barry and his always hilarious Year in Review, we’ll organize these stories by month.

Without further ado, here’s a look at the stories that grabbed our attention in 2018.
Continue Reading

Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana.  And what a week it was!

Michigan legalized recreational cannabis, Utah and Missouri voted yes on medical marijuana, and several pro-legalization candidates were elected as governors.  Meanwhile, North Dakota voted against legalization and Rep. Dana

Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana.

You may recall that the Food and Drug Administration is asking for comments on rescheduling cannabis.  Many times, agency requests for comments are met with a deafening silence.  This is not one of those times.

Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana.

Here at The Blunt Truth, we are well aware of the difficulties cannabis businesses face in obtaining financial services.  It turns out, even political groups that support marijuana legalization can face a problem with banks.

This is Washington, and we do like to speak in initials.  A plain English translation of the title of this piece would read “FDA ‘places FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 percent tetrahydrocannabinols in Schedule V.’”  DEA Final Order, Docket No. DEA-486 Schedule V drugs include cough medicine with codeine and many pain relievers that still require a prescription.  So, really what this order does is allow doctors in the US legally to prescribe the recently approved epilepsy drug, Epidiolex, and allows pharmacies, rather than marijuana dispensaries, legally to sell the drug.
Continue Reading